Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 711 of 6351
-
New pill aims to stop the itch of prurigo nodularis
Disease control OngoingThe purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can olive oil and walnuts shield the brain from stroke and memory loss?
Disease control Recruiting nowThe study is divided into two phases: Phase 1 (observational) and Phase 2 (dietary intervention). The goal of Phase 1 is to assess the nutritional status and dietary habits of two cohorts of patients with CADASIL and CAA. A specific aim is to evaluate adherence to the Mediterrane…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug acolbifene takes on tamoxifen in breast cancer prevention trial
Prevention Recruiting nowThis phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for patients at increased risk for breast cancer is to undergo yearly breast magnetic …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Can a VR headset turn a painful scope into a calmer experience?
Symptom relief CompletedHaemorrhagic rectocolitis is an inflammatory bowel disease that continuously affects the rectum and colon, with lesions that extend variably from the rectum into the upstream colon. This disease requires repeated assessment of both clinical activity (transcribed by the clinical M…
Sponsor: Centre Hospitalier Departemental Vendee • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
New weekly Weight-Loss shot shows promise in Mid-Stage trial
Disease control CompletedThis study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a weekly pill replace daily HIV meds? new study aims to find out.
Disease control OngoingThe goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with human immunode…
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSCA-CAR T cells), plus or minus radiation, in treating patients with castration-re…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New combo therapy aims to wipe out rectal cancer before surgery
Disease control OngoingA Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug could shrink rare joint tumors without surgery
Disease control OngoingThis is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewe…
Phase 3 • Sponsor: SynOx Therapeutics Limited • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Promising new therapy targets rare, aggressive cancers
Disease control OngoingTo find out if ubamatamab, given by itself or in combination with cemiplimab, can help to control the disease in participants with renal medullary carcinoma (RMC) and epithelioid sarcoma (ES).
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo attack on aggressive breast cancer shows promise in early trial
Disease control Recruiting nowThis study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response(PCR) of Adjuvant treatment of TNBC breast cancer with Toripalimab combined with neoadjuvant chemotherapy, including the incid…
Phase 2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Can a special laser ease stubborn back pain?
Symptom relief CancelledPatients who come to Tavşanlı Assoc. Prof. Dr. Mustafa Kalemli State Hospital, Physical Therapy, and Rehabilitation Department who have been diagnosed with Chronic Low Back Pain by a physician will be included. Patients will be divided into two groups by the physician: conservati…
Sponsor: Kutahya Health Sciences University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a targeted antibody take on glioblastoma?
Disease control OngoingThe purpose of this clinical trial is to evaluate the safety and tolerability of amivantamab and to determine the preliminary antitumour activity of amivantamab administered at the recommended Phase 2 dose (RP2D). In the Phase 1b of this study a biomarker defined arm will be open…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Teachers as frontline mental health providers: a new experiment in schools
Symptom relief Recruiting nowPurpose: The purpose of this research is to pilot test a novel, alternative, potentially sustainable system of teacher-delivered, task-shifted child mental health care. Participants: \~300 estimated Procedures: This is a RE-AIM (Reach, Effectiveness, Adoption, Implementation, M…
Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New pill aims to keep narcolepsy patients awake and steady
Symptom relief CompletedThe main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected…
Phase 3 • Sponsor: Takeda • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New oral weight loss pill shows promise in Mid-Stage trial
Disease control CompletedA Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age wh…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New targeted pill shows promise for rare bile duct cancer in Real-World study
Disease control Recruiting nowCholangiocarcinoma is a rare and aggressive tumor of the bile duct associated with a poor prognosis and very limited treatment options. The IDH1 inhibitor ivosidenib provides a new, targeted treatment option for this disease. Ivosidenib was approved by European Medicines Agency (…
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New shot could bring major relief for severe eczema sufferers
Disease control OngoingThis is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation…
Phase 3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can a radioactive drug seek out and attack solid tumors?
Disease control OngoingThis is an open-label, uncontrolled, multi-center, phase 1a MNPR-101-PCTA-177Lu dose-escalation study in patients with solid tumor cancers. Patients must have participated in the imaging study MNPR-101-D001 (actively recruiting, diagnostic study of MNPR-101-DFO\*-89Zr). * TITE-B…
Phase 1 • Sponsor: Monopar Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New triple therapy aims to tackle tough leukemia mutation
Disease control Recruiting nowThe FMS tyrosine kinase 3 (FLT3) gene mutation occurs in 30% of newly diagnosed AML patients, leading to a higher relapse rate and mortality rate. In the past, multi-drug combination chemotherapy regimens had limited efficacy in newly diagnosed AML patients with FLT3 mutations, e…
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC